Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: Results from Veterans Affairs Cooperative Study 394

James B. Lohr, Michael P. Caligiuri, Robert Edson, Philip Lavori, Lenard A. Adler, John Rotrosen, Robert Hitzemann

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Predictors for the development of tardive dyskinesia (TD) have been studied extensively over the years, yet there are few studies of predictors of the course of TD after it has developed. Moreover, few studies have examined predictors of the course of other extrapyramidal side effects (EPS) in patients maintained on neuroleptics. The purpose of this study was to determine which modifiable variables are important in the prediction of EPS in patients with persistent TD over a period of as long as 2 years. One hundred fifty-eight patients enrolled in the Veterans Affairs Cooperative Study 394 were included in this study. A linear mixed-effects (LME) analysis to estimate the Abnormal Involuntary Movement Scale score (for TD severity), Simpson-Angus Scale (for parkinsonism severity), and Barnes Akathisia Scale at any given time after intake assessment was performed. The severity of each of the TD and EPS outcomes at any given visit was predicted by their respective baseline severity scores. Additional predictors of a favorable course of TD included lower doses of antipsychotic medications and use of anticholinergic medications. Other predictors of a favorable course of EPS included younger age and the use of atypical antipsychotic medication (for rigidity) and the use of anticholinergic medication (for tremor). These findings indicate that clinician-modifiable factors related to medication usage can influence the outcome of TD and EPS in patients with persistent TD.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume22
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Veterans
Antipsychotic Agents
Cholinergic Antagonists
Therapeutics
Psychomotor Agitation
Tardive Dyskinesia
Parkinsonian Disorders
Tremor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia : Results from Veterans Affairs Cooperative Study 394. / Lohr, James B.; Caligiuri, Michael P.; Edson, Robert; Lavori, Philip; Adler, Lenard A.; Rotrosen, John; Hitzemann, Robert.

In: Journal of Clinical Psychopharmacology, Vol. 22, No. 2, 2002, p. 196-200.

Research output: Contribution to journalArticle

Lohr, James B. ; Caligiuri, Michael P. ; Edson, Robert ; Lavori, Philip ; Adler, Lenard A. ; Rotrosen, John ; Hitzemann, Robert. / Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia : Results from Veterans Affairs Cooperative Study 394. In: Journal of Clinical Psychopharmacology. 2002 ; Vol. 22, No. 2. pp. 196-200.
@article{1e3365d554e946d3a31e96fa8684768f,
title = "Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: Results from Veterans Affairs Cooperative Study 394",
abstract = "Predictors for the development of tardive dyskinesia (TD) have been studied extensively over the years, yet there are few studies of predictors of the course of TD after it has developed. Moreover, few studies have examined predictors of the course of other extrapyramidal side effects (EPS) in patients maintained on neuroleptics. The purpose of this study was to determine which modifiable variables are important in the prediction of EPS in patients with persistent TD over a period of as long as 2 years. One hundred fifty-eight patients enrolled in the Veterans Affairs Cooperative Study 394 were included in this study. A linear mixed-effects (LME) analysis to estimate the Abnormal Involuntary Movement Scale score (for TD severity), Simpson-Angus Scale (for parkinsonism severity), and Barnes Akathisia Scale at any given time after intake assessment was performed. The severity of each of the TD and EPS outcomes at any given visit was predicted by their respective baseline severity scores. Additional predictors of a favorable course of TD included lower doses of antipsychotic medications and use of anticholinergic medications. Other predictors of a favorable course of EPS included younger age and the use of atypical antipsychotic medication (for rigidity) and the use of anticholinergic medication (for tremor). These findings indicate that clinician-modifiable factors related to medication usage can influence the outcome of TD and EPS in patients with persistent TD.",
author = "Lohr, {James B.} and Caligiuri, {Michael P.} and Robert Edson and Philip Lavori and Adler, {Lenard A.} and John Rotrosen and Robert Hitzemann",
year = "2002",
doi = "10.1097/00004714-200204000-00014",
language = "English (US)",
volume = "22",
pages = "196--200",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia

T2 - Results from Veterans Affairs Cooperative Study 394

AU - Lohr, James B.

AU - Caligiuri, Michael P.

AU - Edson, Robert

AU - Lavori, Philip

AU - Adler, Lenard A.

AU - Rotrosen, John

AU - Hitzemann, Robert

PY - 2002

Y1 - 2002

N2 - Predictors for the development of tardive dyskinesia (TD) have been studied extensively over the years, yet there are few studies of predictors of the course of TD after it has developed. Moreover, few studies have examined predictors of the course of other extrapyramidal side effects (EPS) in patients maintained on neuroleptics. The purpose of this study was to determine which modifiable variables are important in the prediction of EPS in patients with persistent TD over a period of as long as 2 years. One hundred fifty-eight patients enrolled in the Veterans Affairs Cooperative Study 394 were included in this study. A linear mixed-effects (LME) analysis to estimate the Abnormal Involuntary Movement Scale score (for TD severity), Simpson-Angus Scale (for parkinsonism severity), and Barnes Akathisia Scale at any given time after intake assessment was performed. The severity of each of the TD and EPS outcomes at any given visit was predicted by their respective baseline severity scores. Additional predictors of a favorable course of TD included lower doses of antipsychotic medications and use of anticholinergic medications. Other predictors of a favorable course of EPS included younger age and the use of atypical antipsychotic medication (for rigidity) and the use of anticholinergic medication (for tremor). These findings indicate that clinician-modifiable factors related to medication usage can influence the outcome of TD and EPS in patients with persistent TD.

AB - Predictors for the development of tardive dyskinesia (TD) have been studied extensively over the years, yet there are few studies of predictors of the course of TD after it has developed. Moreover, few studies have examined predictors of the course of other extrapyramidal side effects (EPS) in patients maintained on neuroleptics. The purpose of this study was to determine which modifiable variables are important in the prediction of EPS in patients with persistent TD over a period of as long as 2 years. One hundred fifty-eight patients enrolled in the Veterans Affairs Cooperative Study 394 were included in this study. A linear mixed-effects (LME) analysis to estimate the Abnormal Involuntary Movement Scale score (for TD severity), Simpson-Angus Scale (for parkinsonism severity), and Barnes Akathisia Scale at any given time after intake assessment was performed. The severity of each of the TD and EPS outcomes at any given visit was predicted by their respective baseline severity scores. Additional predictors of a favorable course of TD included lower doses of antipsychotic medications and use of anticholinergic medications. Other predictors of a favorable course of EPS included younger age and the use of atypical antipsychotic medication (for rigidity) and the use of anticholinergic medication (for tremor). These findings indicate that clinician-modifiable factors related to medication usage can influence the outcome of TD and EPS in patients with persistent TD.

UR - http://www.scopus.com/inward/record.url?scp=0036214968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036214968&partnerID=8YFLogxK

U2 - 10.1097/00004714-200204000-00014

DO - 10.1097/00004714-200204000-00014

M3 - Article

C2 - 11910266

AN - SCOPUS:0036214968

VL - 22

SP - 196

EP - 200

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -